Save time and money with
Med Tech Market
Research
MedTech Business intelligence
supplied by GlobalData
Latest reports
Ischemic Cerebral Stroke Global Clinical Trials Review
The
databook offers a preliminary coverage of disease clinical trials by
their phase, trial status, prominence of the sponsors and also provides
briefing pertaining to the number of trials for the key drugs for
treating Ischemic Cerebral Stroke. Aug 2014
Multiple Sclerosis Global Clinical Trials Review
The databook
offers a preliminary coverage of disease clinical trials by their phase,
trial status, prominence of the sponsors and also provides briefing
pertaining to the number of trials for the key drugs for treating
Multiple Sclerosis. Aug 2014
Market forecast for
Aricept
Eisai’s Aricept (donepezil hydrochloride) is a piperidine derivative
that acts centrally as a reversible AChEI. 6 Dec 2013
Market forecast for
Exelon
Exelon (rivastigmine, rivastigmine tartrate), which is manufactured
and marketed by Novartis, is a reversible ChEI indicated for the
treatment of mild to moderate dementia of the Alzheimer's type. 6 Dec
2013
Market
forecast for Razadyne/ Reminyl
Razadyne (also known as Reminyl) is a reversible, competitive AChEI
indicated for the treatment of mild to moderate AD. The exact MOA of
galantamine is not known. 6 Dec 2013
MediFocus: Medical devices for the treatment of obesity
This report offers a comprehensive analysis of the global
obesity medical device market, including development and approval of
artificial fullness devices, deep brain stimulation devices, endoscopic
surgical devices, gastric electrical stimulation devices. 2 Oct 2013
PharmaSphere: Asia Pacific Deal Trends, 2004–2013
An
in-depth analysis of the key deals that took place in the region during
the last decade. The Asia Pacific Region is increasingly seen as a
potential source of revenue growth for global pharma firms. 1 Oct 2013
Nascent Alzheimer's disease biomarker market provides
opportunities for pharma companies
From a commercial
standpoint, the Alzheimer's disease (AD) biomarkers market is still
relatively young. Biomarkers for Alzheimer's disease can be classified
in terms of pathological mechanism and also in terms of the assay
technology used to detect and assess the biomarker.
Read more... 5 Sept 2013
EpiCast Report: Dry Eye Syndrome — Epidemiology Forecast to 2022
Dry eye syndrome, also known as keratoconjunctivitis sicca (KCS), is a
multi-factorial disease of the eye caused by dryness, decreased tear
production, or increased tear film evaporation. It results in symptoms
of discomfort such as visual disturbance and tear film instability.
PharmaFocus: Vaccine Adjuvants in Infectious Disease
Originally discovered by Glenny in the 1920s, vaccine adjuvants have
remained the pharmaceutical industry’s “dirty little secret”. Today,
vaccine adjuvants are credited with helping to bolster the immune
response in the host post-vaccination.
EpiCast Report: Alzheimer’s Disease — Epidemiology Forecast to 2022
The global prevalence of dementia is estimated to be 3.9% in people age
60 years and older, with an overall Alzheimer’s disease prevalence of
9.7% in the US, 4.4% in Europe, and 3.4% in developing countries.
PharmaLeaders: CRO
benchmark report — financial benchmarking & competitive landscape
assessment of leading CROs
Analysis of the key drivers and trends shaping the global CRO
market; including biologics manufacturing, emerging markets, and
eClinical technologies.
EpiCast: Chronic Kidney Disease — Epidemiology Forecast to 2022
The Chronic Kidney Disease EpiCast Report and EpiCast
Model provide an overview of the risk factors and global trends of
chronic kidney disease in the six major markets (6MM) (US, France,
Germany, Italy, Spain, and UK). It includes a 10-year epidemiological
forecast (2012–2022) of the prevalent cases of chronic kidney disease
segmented by age.
Type 2 diabetes – global drug forecast and market analysis
to 2022
Overview of Type 2
diabetes, including epidemiology, etiology,
pathophysiology, symptoms, diagnosis, and treatment guidelines.
Annualized therapeutics market revenue, annual cost of therapy and
treatment usage pattern data from 2012 to 2022.
Netherlands embracing generics to counter growing healthcare
costs
With the elderly making up an ever
greater share of the country’s population, the Netherlands is
increasingly supporting its generics sector in an attempt to address
mounting healthcare costs, says a new report from industry
experts GlobalData.
Denmark healthcare market bouncing back after recession
The Danish healthcare market is showing healthy signs of recovery following
the crippling global financial crisis of 2008, says the latest report
from business intelligence providers GlobalData:
Healthcare, Regulatory and Reimbursement Landscape — Denmark.
Nanotechnology Cookbook. Practical, Reliable and Jargon-free Experimental Procedures. Elsevier Science and Technology, June 2012, Pages: 324. 100+ detailed recipes for synthesis of basic nanostructured materials, enables readers to pick up the book and get started on a preparation immediately. A cookbook, by design and structure the work is easy to use, familiar and compact.
Rheumatoid
Arthritis Therapeutics — Pipeline Assessment and Market Forecasts to
2018
Rheumatoid Arthritis Therapeutics Market is
Forecast to Show Moderate Growth Until 2018. GlobalData’s analysis
suggests that the global rheumatoid arthritis therapeutics market was
worth $10.3 billion in 2010 and forecast to grow at a CAGR of 3.8% to
reach $13.8 billion by 2018. The high growth rate during 2005-2010 is
primarily attributed to the launch of biologics such as Enbrel
(etanercept), Remicade(infliximab),
Humira (adalimumab) and Rituxan (rituximab).
Read more ...